Literature DB >> 7562758

Is it possible to reduce observer variability in skin score assessment of scleroderma? The ad hoc International Group on the Assessment of Disease Outcome in Scleroderma.

A Silman1, M Harrison, P Brennan.   

Abstract

OBJECTIVE: A total skin thickness score based on summating the numerical severity grade at a specific number of skin sites is a widely accepted method of disease assessment in scleroderma. Our aim was to simplify the modified Rodnan skin thickness score (grade 0-3 at 17 sites) by either (1) reducing the number of grades or (2) reducing the number of sites, and to increase agreement without losing precision.
METHODS: Eight patients were examined in random order by 16 experienced clinicians using the modified Rodnan method. The data were analyzed to determine (1) whether there was an improvement in agreement by reducing severity grades to a 0-2 scale, (2) whether the precision of the score could be maintained by using a reduced number of sites.
RESULTS: Collapsing adjacent grades from the 0-3 scale to generate 3 new 0-2 scales performed similarly (intraclass correlation coefficients 0.66-0.72). A regression analysis showed that 95% of the variance in skin score can be predicted by inclusion of scores from just 5 sites: forearms, lower legs, anterior chest, upper arms, and fingers.
CONCLUSION: A simpler skin score may be useful in clinical studies depending on the precision required.

Entities:  

Mesh:

Year:  1995        PMID: 7562758

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

Review 1.  Biomarkers in the management of scleroderma: an update.

Authors:  Giuseppina Abignano; Maya Buch; Paul Emery; Francesco Del Galdo
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

2.  The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis.

Authors:  László Czirják; Zoltán Nagy; Martin Aringer; Gabriela Riemekasten; Marco Matucci-Cerinic; Daniel E Furst
Journal:  Ann Rheum Dis       Date:  2007-01-18       Impact factor: 19.103

3.  Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials.

Authors:  Marian Kaldas; Puja P Khanna; Daniel E Furst; Philip J Clements; Weng Kee Wong; James R Seibold; Arnold E Postlethwaite; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2009-07-14       Impact factor: 7.580

4.  The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures.

Authors:  Thaschawee Arkachaisri; Soamarat Vilaiyuk; Suzanne Li; Kathleen M O'Neil; Elena Pope; Gloria C Higgins; Marilynn Punaro; Egla C Rabinovich; Margalit Rosenkranz; Daniel A Kietz; Paul Rosen; Steven J Spalding; Teresa R Hennon; Kathryn S Torok; Elaine Cassidy; Thomas A Medsger
Journal:  J Rheumatol       Date:  2009-10-15       Impact factor: 4.666

Review 5.  Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.

Authors:  Ming Zhao; Jiali Wu; Haijing Wu; Amr H Sawalha; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-15       Impact factor: 8.667

6.  Assessment of light touch sensation in the hands of systemic sclerosis patients.

Authors:  Paula Gabriel Silva; Anamaria Jones; Pola Maria Poli Araujo; Jamil Natour
Journal:  Clinics (Sao Paulo)       Date:  2014-09       Impact factor: 2.365

7.  Deep Learning Classification of Systemic Sclerosis Skin Using the MobileNetV2 Model.

Authors:  Metin Akay; Yong Du; Cheryl L Sershen; Minghua Wu; Ting Y Chen; Shervin Assassi; Chandra Mohan; Yasemin M Akay
Journal:  IEEE Open J Eng Med Biol       Date:  2021-03-17

8.  How much of skin improvement over time in systemic sclerosis is due to normal ageing? A prospective study with shear-wave elastography.

Authors:  T Santiago; M Santiago; M Coutinho; M J Salvador; J A P Da Silva
Journal:  Arthritis Res Ther       Date:  2020-03-18       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.